Update on Type 1 Diabetes Trials to Save Beta Cells
|
|
- Matthew Benjamin Waters
- 5 years ago
- Views:
Transcription
1 Benaroya Research Institute Carla Greenbaum MD Seattle, WA Update on Type 1 Diabetes Trials to Save Beta Cells 1552 BC earliest written record of DM 1 st Breakthrough in understanding: 1889 The problem is within the pancreas Cure for diabetes insulin: 1922 insulin 33 yrs Not much change for next 50 years! Human Insulin Home Glucose Monitoring 1980 Marked changes in therapy Insulin pumps DCCT CGMS DKA in type 1 diabetes in US (Rewers A, Pediatrics, May 2008) 54% hospitalized at time of diagnosis 29.4% - DKA at diagnosis Related to $, but > from families with $$$ present in DKA No change in ~20 years Hospitalization for DKA <age 45: almost doubled from (Maldonado, Diabetes Care, 2003) Where are We Today? Average A1c by Age, T1D incidence is rising 3-5% per year Age Intensive Rx Hvidoere DCCT EDIC N=195 N=175 N=1,295^ Sweden (80% of the nation) Los Angeles N=1664 < *^ * 8.6 BDC Denver N=3910 > * yrs; ^the original 14 centers, unchanged compared to 1998 Barbara Davis Center Web Site: REWERS Incidence /100,000/ yr 70 in children aged Finland Sweden Colorado Germany REWERS
2 Finland Type 1 Diabetes Incidence (32 years) Relative Percent Increase 350 Human Insulin Home Glucose Monitoring Insulin pumps Genetic studies: HLA region: Islet Cell Antibodies Pathology studies: Insulitis Insulin Autoantibodies DCCT 1990 GAD65 antibodies, IA Age 1-4 Age 5-9 Age Diabetes Care: 22: CGM Marked changes in therapy Znt8Ab Type 1 diabetes is an immune mediated disease Alopecia areata Ankylosing spondylitis Addisons disease Hemolytic anemia Autoimmune Hepatitis Thrombocytopenic purpura Behcets disease Pemphigus Crohns disease Dermatomyositis Lupus Graves disease Hashimotos Thyroiditis Autoimmune Diabetes Multiple sclerosis Myasthenia gravis Pernicious anemia Polyarteritis Polychondritis Polymyositis Psoriasis Rheumatoid arthritis Scleroderma Sjogren s syndroms Stiff man syndrome Giant cell Arteritis Ulcerative colitis Vasculitis Uveitis Vitiligo Autoimmune Diabetes Multiple Sclerosis Inflammation Wound Repair and Tissue Reconstruction Rheumatoid Arthritis; Lupus; Scleroderma; Polychondritis Type 1 Diabetes Shared Genes Shared Mechanisms
3 macrophage macrophage T Helper T Helper macrophage T Helpe r Invader Attack Resolution Rapid memory response T Helper TIME What goes wrong in autoimmunity? Failure of multiple Check Points Invader is really self and the immune system makes a mistake and starts the whole immune response
4 T Regulatory cells loose the battle with T killer (effector) cells Invader Attack Resolution Rapid memory response T Helper TIME Why does autoimmunity effect only some cells? Why does the immune system make a mistake? Everyone has some cells that recognize self Type 1 diabetes Multiple Sclerosis More survive Inflammatory Bowel Disease (Crohn s and Colitis) More susceptible to immune damage? Parts of these self mimic true invaders? Rheumatoid Arthritis More are made More are activated Likelihood of Autoimmunity Why do T regulatory cells loose the battle? T regulatory cells no good AND/ OR T effector cells too strong Clinical onset of disease
5 Save beta cells in those genetically at risk (Primary Prevention) Save beta cells in antibody positive subjects (Secondary Prevention) STOP progression to autoimmunity/beta Clinical onset of cell disease destructio STOP clinical disease Save beta cells after clinical disease (Tertiary Prevention-A) Save beta cells that are replaced after clinical disease (Tertiary Prevention-B) STOP complicati STOP Clinical onset complications of disease How long until NO detectable C-peptide? Persistence of Fasting C-peptide in Antibody Positive Youth % Preserved DCCT: <0.07 pm DCCT NHANES 5 th : 0.33 pm NHANES 50 th : 0.63 pm NHANES 5th NHANES 50th Duration of Diabetes (Months) By 2 years: ~80% with C-peptide Even by 4 years.~50% still with 29 C-peptide N =
6 Three Key Requirements for Saving Beta cells at each stage Clinical onset of disease? 1. Know the natural history 2. Identify those at risk 3. Test therapies that balance risk/benefit Primary Prevention Studies 230 babies: First degree relative with T1DM: high risk genes When not breast feeding take hydrolyzed formula or regulator formula Role of the GUT and microbiome Hydrolyzed protein Hydrolyzed protein Pre-Point Point Study TRIGR study 9/109 diabetes 7/113 diabetes NIP study Knip et al, NEJM, 2010 TRIGR PILOT Full Study results to come No Difference Save beta cells after clinical disease (Tertiary Prevention-A) Tertiary Prevention Studies: Diabetes Stop complications Stop complications Clinical onset of disease Why preserve?
7 Diabetes Control and Complications Trial Does Intensive Diabetes Management (GOAL HbA1c <7%) reduce complications? YES But, this is done at the risk of hypoglycemia DCCT: NEJM, : marked reduction in retinopathy, nephropathy 2005: Marked reduction in cardiovascular disease DCCT: NEJM, 1993 Benefits of β-cell Preservation in DCCT Hypoglycemia with Coma/Seizure 62% Risk Reduction UNLESS you still have beta cell function!!!! Rate per 100 pt years Ann Int Med 128: , 1998 Diabetes 53: , 2004 Conventional Intensive Intensive With insulin secretion No insulin secretion Cumulative Incidence (%) DCCT Intensive Therapy Group Sustained 3+ Step Retinopathy Progression Risk Reduction: 79% (CI: 9, 95) p < No insulin secretion Year of Follow-up With insulin secretion Diabetes 53: , 2004 TrialNet Why preserve? Among DCCT subjects in the intensive treatment group: Prevents short term complications Prevents long term complications 62% less hypoglycemia 79% Risk reduction in retinopathy
8 Glucose Control impacts beta cell survival Better diabetes control Poor diabetes control Halloran N Engl J Med 2004, 351: Preservation of Beta Cell Function by Monoclonal-Antibody Group Anti-CD3 Immune Tolerance Network (Macrogenics: Protege Studies) Anti T cell therapy Insulin Secretion Insulin Secretion Control Group 9/12 stable or increase 2/12 stable or increase [hokt3γ1(ala-ala)] Herold, KC et al, New England Journal of Medicine, 2002 C-peptide Preservation of Insulin Secretion with Rituximab * * pmol/ml Anti B cell therapy *p < in months * Overall p < Ritux Placebo Antigen based therapy GAD65-Alum Alum Treatment 69 subjects, up to 18 months from diagnosis; Ages And lower HbA1c with less insulin 47 Diamyd: DiaPrevent Study Ludvigsson et al NEJM 2008 GAD65 Study 48
9 Selected Trials to report results 2011 Abatacept CTLA4-Ig Phase II(NIH TrialNet) Diamyd GAD-alum Phase III(Diaprevent) Phase III(European) Phase II(NIH TrialNet) DiaPep277 HSP peptide Phase III IL-2 + Rapamycin Phase I(NIH, ITN) Prochymal Mesenchymal stem Phase II Teplizumab Anti-CD3 Phase II/III(Protégé) Phase II (Protégé encoure) Phase II (NIH ITN, AbATE) Otelixizumab Anti-CD3 Phase III(Defend-1) 49 Selected new onset Trials underway Meticulous Glucose Control (TN and DirecNet) Anti-inflammatory Anakinra (Europe) Canakinumab (TrialNet) Alpha-1 antitrypsin (ITN) Proton pump inhibitor + DPP IV inhibitor (Sanford) Cord blood (UF, Gainesville) Thymoglobulin (ITN) Naturally processed peptides (DVDC, UK) 50 DirectNet Phase II trial: Metabolic Rest: closed loop pump and sensors B. Buckingham, Stanford Diagnosed within past week! Randomized trial NIDDK N~66 Primary Outcome: Insulin secretion at 1 year Effect of Intensive vs Conventional Therapy on β-cell Function Ann Int Med 128: , 1998 Conventional N = 303 With 1 5 y duration and C-Peptide pmol/ml Risk Reduction 57% (CI: 39, 71%) P < Intensive UCLA, Yale, Stanford NICHD Palmer Save beta cells in antibody positive subjects (Secondary Prevention) Risk by the age of 20 years stop clinical disease Clinical onset of disease Risk group Autoimmunity T1 DM Population 1:30 1:300 Maternal offspring 1:15 1:50 Paternal offspring Siblings HLA-DR3/4,DQB1*0302 1:5 1:15 Monozygotic twins 1:1 (?) 1:3
10 Families with diabetes 10 ~5% 15x 100 Newly diagnosed patients with type 1 diabetes 90 Families without diabetes 0.3% Save beta cells in antibody positive subjects (Secondary Prevention) Previous large Studies ENDIT: Nicotinamide DPT-1: Parenteral Insulin DPT-1: Oral Insulin DIPP: Nasal Insulin 5 year risk estimates More antibodies = greater risk ICA+ relatives <25% Low ICA+, IAA+ relatives 25-50% 35% Intermediate ICA+ relatives with low beta cell function or IGT >50% 60% High Survival Distribution Function n = ab Years Followed 3 ab 1 ab 2 ab 8 QUESTION #1 Question There is no way to know who is going to get type 1 diabetes True or False We CAN determine an individual s risk for diabetes This is done by a combination of genetics (family history), antibody testing, and testing of insulin secretion and glucose.
11 Risk in Family members Number of antibodies increased risk Low insulin secretion increased risk Abnormal glucose increased risk Free tests available Question Who should get tested? a. My daughter has type 1 diabetes, my other children should be tested a. I should get tested. My cousin has type 1 diabetes a. I am an adult with type 1 diabetes. My kids are all grown they don t need to be tested. Answer : Who should get tested? X a. My daughter has type 1 diabetes, my other children should be tested. Your other children and you and her dad and aunts, uncles, cousins, nieces and nephews. X b. I should get tested. My cousin has type 1 diabetes c. I am an adult with type 1 diabetes. My kids are all grown they don t need to be tested. No, half of all type 1 diabetes occurs in adults. If you have a family member up to age 45, they should be tested (including grandkids!) Which family members should be screened? MOM (under age 45) Sisters and Brothers (under age 45) Nieces and Nephews (< age 20) DAD (under age 45) Children (< age 45) Grandchildren (< age 20) Half-sibling < age 20 Aunts and Uncles (< age 20) Cousins < age 20 1 ST 2 nd ST Degree relatives (ages 1-45) nd Degree relatives (ages 1-20) Blood draw ~4% positive Antibodies 1 ST 2 nd ST Degree relatives (ages 1-45) nd Degree relatives (ages 1-20) Blood draw ~4% positive Antibodies Very High Risk AntiCD3 Intermediate Risk Oral Insulin Low Risk Close monitoring Very High Risk Intermediate Risk Oral Insulin Low Risk GAD65-Alum GAD65-Alum
12 Save beta cells in antibody positive subjects (Secondary Prevention) Oral Insulin Oral Tolerance: Mode of Action Protective Cytokines Oral Antigen Clinical onset of disease Regulatory Lymphocytes Inhibition of β-cell Autoimmunity and Prevention of Diabetes Insulin Producing β-cells Autoimmune Lymphocytes Diabetes Prevention Trial type 1 diabetes <25% Low ICA+, IAA+ relatives ICA+ relatives 25-50% ORAL INSULIN Intermediate ICA+ relatives with low beta cell function >50% High Survival Distribution Function DPT-1 Oral Study to Diabetes By Treatment Diabetes Care 2005; 28: Years Followed NO BENEFIT Treated Control Yet, Marked Benefit in Subjects with high IAA Proportion Free of Diabetes Log-rank P=0.01 Peto Pr. P=0.01 IAA >= 300 Hazard Ratio: 0.41 (0.21, 0.80) N=63 (Ins.) and 69 (Plac.) Oral Insulin Placebo 1 ST 2 nd ST Degree relatives (ages 1-45) nd Degree relatives (ages 1-20) Blood draw Very High Risk AntiCD3 Intermediate Risk ~4% positive Antibodies Low Risk Years
13 Survival Distribution Function Abnormal Glucose Tolerance = VERY high risk Control Treated Years Followed New Engl J Med 2002; 346: Intervention Observation Updated Data from Phase I/II Trial of Anti-CD3 in new onset T1DM AUC (pmol/ml/240min) * * * Anti-CD3 Comparison * p<0.02 Month Herold et al. Diabetes 2005; 54: Very High Risk AntiCD3 Diabetes Prevention Trials Intermediate Risk Oral Insulin GAD65-Alum Low Risk Close monitoring ~1,500,000 individuals with Type 1 diabetes in US 200,000 Relatives Needed Health Providers Health Providers Recommend getting involved in TrialNet Why be tested for risk? Early Detection Eligibility for prevention Providers Help research move forward
14 Participant and Parent Experience in DPT-1 trials DPT-1 Oral Trial 35-50% 5 yr risk OGTT every 6 months DPT-1 Parenteral Trial >50% 5 yr risk oral insulin/placebo Once yearly 4 days IV Random assignment insulin and daily sq BID 95-96% parents stressed with news (resolved over time) No placebo Relatively easy decision to participate 93% of parents best part of study : monitoring for development of T1DM Almost half found random assignment difficult % parents would recommend study to friends Bennett Johnson et al, Diabetes Care, Sept 2007; Pediatric Diabetes, 2009 Diabetes Support Groups JDRF events (walks, parties) ADA events (camps, walks, expo) Children with Diabetes Taking control of your diabetes Pharmacies Media (radio, TV, print) Social Networking Turku, Finland Malmo, Sweden Melbourne Bristol, UK Milan, Italy Munich, Germany NIDDK NIAID NICHD NCRR Our son was diagnosed when he was 4 years old. He has been absolutely wonderful about dealing with his diabetes NOTHING stops this child Before we left his Endo appointment this past Wednesday, he says, Mom, what does cure mean? I explained that it means when scientists find out how to stop a disease or problem and then it is gone forever. He looks at me with this silly expression on his face and says, Well, do you think that you can tell my doctor to speed things up a little? Paraphrased from Children with Diabetes Weekly Newsletter (April 14, 2010)
15 Type 1 diabetes is an autoimmune disease Risk for Type 1 diabetes can be predicted Studies underway to save beta cells Prevention Prolong insulin secretion Let families know about clinical research Individuals WITH diabetes Relatives WITHOUT diabetes Diabetes Clinical Research Team Srinath Sanda MD Jennifer Bollyky MD Angela Dove Jani Klein Deborah Emily Hefty Batts Mary Ramey Kristen Kuhns Marli McCulloch -Olson Marilyn Christine Heather Rebecca Reeve Webber Vendettuoli Walker Brochures, posters, flyers Business cards Actively enroll subjects Article in newsletter Web sites and toll-free phone number Bring research screening to your community
Benaroya Research Institute. Update on Type 1 Diabetes Trials. to Save Beta Cells. Carla Greenbaum MD. Seattle, WA
Benaroya Research Institute Update on Type 1 Diabetes Trials Carla Greenbaum MD Seattle, WA to Save Beta Cells 1552 BC earliest written record of DM 1 st Breakthrough in understanding: 1889 The problem
More informationStaging of Type 1 Diabetes: Clinical Implications. April Deborah Hefty, MN, RN, CDE.
Staging of Type 1 Diabetes: TT Clinical Implications April 2016 Deborah Hefty, MN, RN, CDE dhefty@benaroyaresearch.org BRI s major contributions to type 1 diabetes research Identified type 1 diabetes susceptibility
More informationUpdate on Type 1 Diabetes Trials to Save Beta Cells. DKA in type 1 diabetes in US. 33 yrs. Not much change for next 50 years!
Benaroya Research Institute Carla Greenbaum MD Seattle, WA Update on ype 1 Diabetes rials to Save Beta Cells 1552 BC earliest written record of DM 1 st Breakthrough in undstanding: 1889 he problem is within
More informationImmune Modulation of Type1 Diabetes
Immune Modulation of Type1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine Ideal Therapeutic
More informationYes, We are Close to Preventing Diabetes!
Yes, We are Close to Preventing Diabetes! Peter A. Gottlieb, MD Barbara Davis Center University of Colorado Health Sciences Center Denver, CO Practical Ways to Achieve Targets in Diabetes Care, Keystone,
More informationEarly Diagnosis and Intervention for Type 1 Diabetes (T1D) Progress from T1D TrialNet
Early Diagnosis and Intervention for Type 1 Diabetes (T1D) Progress from T1D TrialNet Wei Hao, M.D., Ph.D. Clinical Investigator Diabetes Clinical Research Program The TrialNet Clinical Network Hub & the
More informationDr Dario Tuccinardi University Campus Bio-Medico of Rome
Dr Dario Tuccinardi University Campus Bio-Medico of Rome d.tuccinardi@unicampus.it Topics to be discussed Epidemiology (increase in incidence) Genetics (more cases with moderate HLA risk alleles) Pathogenesis
More informationNew targets for prevention of type 1 diabetes George S. Eisenbarth Barbara Davis Center Unversity Colorado
New targets for prevention of type 1 diabetes George S. Eisenbarth Barbara Davis Center Unversity Colorado WEB BOOK: Immunology of Type 1 Diabetes HTTP://WWW.BARBARADAVISCENTER.ORG Board Member/Advisory
More informationAltering The Course Of Type 1 Diabetes
Altering The Course Of Type 1 Diabetes JDRF TypeOneNation Summit 09.18.16 Stephen E. Gitelman, MD UCSF sgitelma@.ucsf.edu Today s Agenda My story The path to Type 1 Diabetes Prevention efforts New-onset
More informationPrediction and Prevention of Type 1 Diabetes. How far to go?
Prediction and Prevention of Type 1 Diabetes. How far to go? Peter Colman Diabetes and Endocrinology Royal Melbourne Hospital Royal Melbourne Hospital Lancet, Saturday 30 th November 1974; p. 1279-1282
More informationPlease fill in all the blanks or check the appropriate boxes, the starred fields (*) are optional:
Alopecia Areata Registry: Short Form Questionnaire: Date of Revision: June 2010 Page 1 of 5 This questionnaire is only for people who live in the U.S.A and who have personal or family documentation of
More informationImmune therapy in type 1 diabetes mellitus.
Immune therapy in type 1 diabetes mellitus. Lernmark, Åke; Elding Larsson, Helena Published in: Nature Reviews Endocrinology DOI: 10.1038/nrendo.2012.237 2013 Link to publication Citation for published
More informationEarly Diagnosis of T1D Through An3body Screening
Early Diagnosis of T1D Through An3body Screening Andrea Steck, M.D. Barbara Davis Center for Childhood Diabetes Keystone Conference July 15, 2017 Presenter Disclosure Andrea Steck Disclosed no conflict
More informationJDRF Research. Jessica Dunne, Ph.D. Director, Discovery Research
JDRF Research Jessica Dunne, Ph.D. Director, Discovery Research Saturday, March 11, 2017 Hello JESSICA DUNNE, PH.D. Joined JDRF in September 2008, Lead for Prevention program since its inception in July
More informationJane Buckner, MD, plans to extend research to other diseases of the immune system.
BRING IT ON. SPRING 2016 VOLUME 8 NO. 1 NEW PRESIDENT TO BUILD ON RESEARCH LEGACY Beginning this year, Jane Buckner, MD, became president of Benaroya Research Institute at Virginia Mason (BRI). Dr. Buckner,
More informationT1D Clinical Research. Susanne Cabrera, MD Assistant Professor of Pediatrics Medical College of Wisconsin May 6, 2017
T1D Clinical Research Susanne Cabrera, MD Assistant Professor of Pediatrics Medical College of Wisconsin May 6, 2017 Why we need children and teens to participate in research Laboratory rats and mice are
More informationconsequences, including heart disease and stroke.
BRING IT ON. WINTER 2018 VOLUME 10 NO. 4 HOW BRI IS FIGHTING TYPE 1 DIABETES When Merry Malnar was 11 years old, her mom took her in for a routine physical and asked the doctor to test for type 1 diabetes
More informationImmunology 2011 Lecture 20 Autoimmunity 18 October
Immunology 2011 Lecture 20 Autoimmunity 18 October APC Antigen processing (dendritic cells, MΦ et al.) Antigen "presentation" Ag/Ab complexes Antigenspecific triggering B T ANTIGEN Proliferation Differentiation
More informationLEADING TYPE 1 DIABETES RESEARCH GLOBALLY
BRING IT ON. SPRING 2015 VOLUME 7 NO. 1 LEADING TYPE 1 DIABETES RESEARCH GLOBALLY M illions of Americans have diabetes and 5-10 percent of those have type 1 diabetes. Type 1 diabetes, once called juvenile
More informationCOLLABORATION ACCELERATES RESEARCH. STUDYING CELLS TO ELIMINATE ALLERGIES Bill Kwok, PhD, and Erik Wambre, PhD, with Imperial College London
BRING IT ON. FALL 2015 VOLUME 7 NO. 3 COLLABORATION ACCELERATES RESEARCH Benaroya Research Institute at Virginia Mason (BRI) is relatively small compared to large research universities, but its impact
More informationPopulation Screening for T1D and Celiac Disease
Population Screening for T1D and Celiac Disease Marian Rewers, MD, PhD Barbara Davis Center for Diabetes I have no conflicts of interest to report Dysglycemia Opportunities for T1D Prevention Primary Secondary
More informationDiabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated pathologically with specific microvascular and macrovascular complications.
More informationMaking progress: preserving beta cells in type 1 diabetes
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Diabetes and Obesity Making progress: preserving beta cells in type 1 diabetes Mary Pat Gallagher, 1 Robin
More informationChapter 12. Clinical Trials for the Prevention of Type 1 Diabetes
Chapter 12 Clinical Trials for the Prevention of Type 1 Diabetes Selected New Onset Trials as of 2012 Delay Loss C-peptide Cyclosporine Anti-CD3 Anti-CD20 (B cells) CTLA4-Ig (Co-stim block) Cytoxan-ATG-GCSF
More informationDisclosures. Sanofi Advisory Board DSMB for Novo Nordisk Consultant for NeoStem. Altering The Course Of Type 1 Diabetes. UCSF Diabetes Update 4.29.
4/3/15 Altering The Course Of Type 1 Diabetes UCSF Diabetes Update 4.29.15 Stephen E. Gitelman, MD UCSF sgitelma@ucsf.edu Disclosures Sanofi Advisory Board DSMB for Novo Nordisk Consultant for NeoStem 1
More informationFlorida Network Symposium
Desmond Schatz MD University of Florida NE Florida Network Symposium In Conjunction with The 28th Annual Clinical Conference on Diabetes Increase Participation in Clinical Trials Accelerate the Path to
More informationIT ON. BRING. Benaroya Research Institute NO. 1 SPRING HEALTHY IMMUNE SYSTEMS FOR ALL VOLUME 11 NEW PARTNERSHIP
BRING IT ON. SPRING 2019 VOLUME 11 NO. 1 HEALTHY IMMUNE SYSTEMS FOR ALL Benaroya Research Institute at Virginia Mason (BRI) has made game-changing discoveries and significantly expanded our research and
More informationI-Brite - Ocular/Medical/General Information
I-Brite - Ocular/Medical/General Information Na me Date Gender (First) (Middle) (Last) Date of Birth Age Occupation Phone No. Address City State Zip Please describe what is abnormal about the appearance
More informationLONG-TERM INVESTIGATIVE FOLLOW-UP IN TRIALNET (LIFT) (Protocol TN-16)
TrialNet Protocol TN16 LIFT Protocol Version: 2.0 12FEB2015 LONG-TERM INVESTIGATIVE FOLLOW-UP IN TRIALNET (LIFT) (Protocol TN-16) Version: 2.0 12FEB2015 Sponsored by the National Institute of Diabetes
More informationChapter 11. Prediction of Type 1A Diabetes: The Natural History of the Prediabetic Period
Chapter 11 Prediction of Type 1A Diabetes: The Natural History of the Prediabetic Period Greenbaum et al Diabetes June 11, 212 Fall in C peptide During First 2 Years From Diagnosis: Evidence of at Least
More informationType 1 Diabetes TrialNet Long-term Investigative Follow-up in TrialNet (LIFT)
1 Type 1 Diabetes TrialNet Long-term Investigative Follow-up in TrialNet (LIFT) Type 1 Diabetes TrialNet Researchers in this study are part of a larger group called Type 1 Diabetes TrialNet. TrialNet is
More informationBDC Keystone Genetics Type 1 Diabetes. Immunology of diabetes book with Teaching Slides
BDC Keystone Genetics Type 1 Diabetes www.barbaradaviscenter.org Immunology of diabetes book with Teaching Slides PRACTICAL Trailnet screens relatives and new onset patients for autoantibodies and HLA
More informationDiabetes Mellitus in the Pediatric Patient
Diabetes Mellitus in the Pediatric Patient William Bryant, M.D. Chief of Section Pediatric Endocrinology Children s Hospital at Scott & White Texas A&M University Temple, Texas Disclosures None Definitions
More informationDepleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere?
Depleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere? Lernmark, Åke Published in: Diabetes DOI: 10.2337/db13-1207 Published: 2013-01-01 Link to publication Citation
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationImmune tolerance, autoimmune diseases
Immune tolerance, autoimmune diseases Immune tolerance Central: negative selection during thymic education deletion of autoreactive B-lymphocytes in bone marrow Positive selection in the thymus Negative
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationWhat is New in Type 1 Diabetes? Prof. Åke Lernmark
What is New in Type 1 Diabetes? Lunds Universitet/CRC Skånes University Hospital SUS Malmö, Sweden 1 What s new in type 1 diabetes? Is the disease still increasing? What is the etiology? What is the pathogenesis?
More informationChapter 10. Humoral Autoimmunity 6/20/2012
Chapter 10 Humoral Autoimmunity 6/20/2012 DIPP Populations Study: Quartile Levels Insulin Autoantibodies (6 month post first IAA) and progression to Diabetes Parrika et al Diabetologia 2012 MSD ELECTROCHEMILUMINESCENT
More informationResidual C-peptide in type 1 diabetes: what do we really know?
Pediatric Diabetes 2014: 15: 84 90 doi: 10.1111/pedi.12135 All rights reserved 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. Pediatric Diabetes Review Article Residual C-peptide in type
More informationTrialNet NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES: A PATHWAY TO PREVENTION
TrialNet NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES: A PATHWAY TO PREVENTION TYPE 1 DIABETES TRIALNET Researchers in this study are part of a larger group called Type 1 Diabetes TrialNet.
More informationIT ON. BRING FALL NO. 3 VOLUME 6 SCIENTISTS IDENTIFY CELLS CAUSING RHEUMATOID ARTHRITIS RHEUMATOID ARTHRITIS IN JOINT
BRING IT ON. FALL 2014 VOLUME 6 NO. 3 SCIENTISTS IDENTIFY CELLS CAUSING RHEUMATOID ARTHRITIS R esearchers at Benaroya Research Institute at Virginia Mason (BRI) used cuttingedge tetramer technology developed
More informationT1D LANDSCAPE HLA INTERVENTION BIOMARKER SECONDARY PREVENTION BIG DATA GLOBAL RESEARCHERS VACCINE TIGEN-SPECIFIC TEDDY TRIAL NET RESEARCH TOOLS
ICROBIOME NOVEL DIAGNOSTICS OUTCOMES XSACKIE B VIRUSES COLLABORATIVE FUNDING ANDSCAPE EENING TOLERIZATION RIMARY PREVENTION PREVENTION LANDSCAPE A GUIDE FOR NAVIGATING EMERGING OPPORTUNITIES NOVEMBER 2014
More informationAutoimmunity and Principles of Transplantation Immunology
Module Code: Module Title: IMM III Autoimmunity and Principles of Transplantation Immunology Module Convenors: Emeritus Professor Jennifer Rolland and Dr Karla Lemmert Discipline: Professor Allan Cripps
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationoimmune_disease
http://en.wikipedia.org/wiki/aut oimmune_disease Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In other words, the
More informationAnti-islet autoantibodies in Japanese type 1 diabetes
15 th Korea Japan Symposium on Diabetes Anti-islet autoantibodies in Japanese type 1 diabetes Eiji Kawasaki, Katsumi Eguchi Nagasaki University Hospital, Nagasaki, Japan November 20 21, 21 2009 Cheju Islend
More informationDysregulation of glucose metabolism in preclinical type 1 diabetes
Pediatric Diabetes 2016: 17(Suppl. 22): 25 30 doi: 10.1111/pedi.12392 All rights reserved Pediatric Diabetes Review Article Dysregulation of glucose metabolism in preclinical type 1 diabetes Veijola R,
More informationTreatment guideline for adult patients with type 1 diabetes?
Treatment guideline for adult patients with type 1 diabetes? Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine ICDM 2014 Treatment
More informationDistinguishing T1D vs. T2D in Childhood: a case report for discussion
Distinguishing T1D vs. T2D in Childhood: a case report for discussion Alba Morales, MD Associate Professor of Pediatrics Division of Pediatric Endocrinology and Diabetes Disclosure I have no financial
More informationMOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism
MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism SCHMAIEL SHIRDEL CONTENT 2 Introduction Autoimmune diseases Classification Involved components Autoimmune
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationDépartement Hospitalo-Universitaire AUToimmune and HORmonal diseases
Uth DHU Département Hospitalo-Universitaire AUToimmune and HORmonal diseases rs DIABETES ADRENAL DISEASES VASCULITIDES L immunomodulation du diabète. Quelles applications? quel avenir? incidence [105/year]
More informationAutoimmune diseases, their pathogenic mechanisms and treatment of unwanted immune responses (Janeway s Immunobiology)
Autoimmune diseases, their pathogenic mechanisms and treatment of unwanted immune responses (Janeway s Immunobiology) Picture source: https://www.klini kum.uniheidelberg.de/fil eadmin/pressest elle/pm_neu/20
More informationAutoimmunity. By: Nadia Chanzu, PhD Student, UNITID Infectious Minds Presentation November 17, 2011
Molecular Mechanisms of Autoimmunity By: Nadia Chanzu, PhD Student, UNITID Infectious Minds Presentation November 17, 2011 Introduction 3m Pick an organ, any organ... Autoimmunity can affect ANY organ/organ
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationCase- history. Lab results
Neda Rasouli, M.D. Associate Professor of Medicine Division of Endocrinology, UC Denver VA_ Eastern Colorado Health Care System Case- history 46 y/o AA male with BMI 37 presented in Oct 2001 with polyuria,
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationIT ON. BRING. Scientists at Benaroya NO. 4 WINTER VOLUME 6 DISCOVERING A BIOMARKER FOR ALLERGIES TYPES OF ALLERGIES SKIN CONTACT INGESTION INJECTION
BRING IT ON. WINTER 2014 VOLUME 6 NO. 4 DISCOVERING A BIOMARKER FOR ALLERGIES Scientists at Benaroya Research Institute at Virginia Mason (BRI) recently received a $2.2 million grant from the National
More informationDesigning An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes.
Designing An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes. Kristin V. Tarbell Immune Tolerance Unit, Diabetes Endocrinology and Obesity Branch, NIDDK Outline Background on type 1 diabetes
More informationAutoimmunity and autoinflammation
Autoimmunity and autoinflammation Primary immunodeficiencies Autoimmunity and autoinflammation 1 Primary immunodeficiencies List of some common abbreviations APECED CAPS CGD CINCA CRMO CVID FCAS FMF HIDS
More informationTargeting the Trimolecular Complex for Immune Intervention. Aaron Michels MD
Targeting the Trimolecular Complex for Immune Intervention Aaron Michels MD Disclosures Research Grant from Novartis. Research Grant from NovoNordisk. Take Home Points Type 1 diabetes is an immunologic
More informationDiabetes Research at Nemours Jacksonville
Diabetes Research at Nemours Jacksonville Larry A. Fox, M.D. Nemours Children s Clinic Jacksonville, FL Medical Director, NE Florida Pediatric Diabetes Center Assoc. Professor of Pediatrics, Mayo College
More informationType 1 Diabetes TrialNet Long-Term Investigative Follow-Up in TrialNet (LIFT)
1 Type 1 Diabetes TrialNet Long-Term Investigative Follow-Up in TrialNet (LIFT) Type 1 Diabetes TrialNet Researchers in this study are part of a larger group called Type 1 Diabetes TrialNet. TrialNet is
More informationNew Drugs for Uveitis. Medical Eye Unit St Thomas Hospital
New Drugs for Uveitis Miles Stanford Medical Eye Unit St Thomas Hospital x Epithelium x x Antigen Y Y Y Y IgG m cd4 IL-2 Y m + IL-12 Cytotoxic T B pmn Ig s PG s. LTB4 O - IL-6 TNFα IFNγγ IL-2 Th1 IL-10
More information. Autoimmune disease. Dr. Baha,Hamdi.AL-Amiedi Ph.D.Microbiology
. Autoimmune disease Dr. Baha,Hamdi.AL-Amiedi Ph.D.Microbiology, Paul Ehrich The term coined by the German immunologist paul Ehrich ( 1854-1915) To describe the bodys innate aversion to immunological
More informationEvgenija Homšak,M.Ph., M.Sc., EuSpLM. Department for laboratory diagnostics University Clinical Centre Maribor Slovenia
Evgenija Homšak,M.Ph., M.Sc., EuSpLM. Department for laboratory diagnostics University Clinical Centre Maribor Slovenia 14th EFLM Continuing Postgraduate Course in Clinical Chemistry and Laboratory Medicine
More informationPrediction and Prevention of Type 1 Diabetes
Prediction and Prevention of Type 1 Diabetes Helping to defuse the diabetes The number of people in the world currently with type 1 diabetes is around 17 million and increasing rapidly. Already there are
More informationDiabetes Prevention & Management of Complications
Diabetes Prevention & Management of Complications Dr Ketan Dhatariya Consultant in Diabetes and Endocrinology NNUH The Planet is Changing IFCC (mmol/mol) = (current value (%) * 10.93) - 23.50 (reported
More informationAlida R Harahap & Farida Oesman Department of Clinical Pathology Faculty of Medicine, University of Indonesia
Alida R Harahap & Farida Oesman Department of Clinical Pathology Faculty of Medicine, University of Indonesia Foreign molecules = antigens Immune response Immune system non-specific specific cellular humoral
More informationThe regenerative therapy of type 1 diabetes mellitus 21April 2017 Girne, Northern Cyprus 53rd Turkish National Diabetes Congress
The regenerative therapy of type 1 diabetes mellitus 21April 2017 Girne, Northern Cyprus 53rd Turkish National Diabetes Congress Thomas Linn Clinical Research Unit Centre of Internal Medicine Justus Liebig
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationExtended Family History of Diabetes and Autoimmune Diseases in Children With and Without Type 1 Diabetes
Diabetes Care Publish Ahead of Print, published online September 27, 2010 Extended Family History of Diabetes and Autoimmune Diseases in Children With and Without Type 1 Diabetes Alhonen Salla, MS 1, Korhonen
More informationDelay of Type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial
Diabetologia (1998) 41: 536±541 Ó Springer-Verlag 1998 Delay of Type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial
More informationFEATURE IMMUNOTHERAPY. The quest for a 20 DIABETES UPDATE SUMMER 2015
FEATURE IMMUNOTHERAPY The quest for a TYPE 1 24 20 DIABETES UPDATE SUMMER 2015 CURE A cure for the autoimmune attack that destroys the beta cells in Type 1 diabetes is a distant goal, but one which could
More informationPathophysiology, Mechanisms for the Induction and Animal Models of
Pathophysiology, Mechanisms for the Induction and Animal Models of Autoimmune Diseases Eun Wha Choi, DVM, PhD Laboratory Animal Research Center, Samsung Biomedical Research Institute (From New therapeutic
More informationComprehensive Screening Detects Undiagnosed Autoimmunity In Adult-onset Type 2 Diabetes
Comprehensive Screening Detects Undiagnosed Autoimmunity In Adult-onset Type 2 Diabetes SRINIVASA R. NAGALLA, MD, PATURI V. RAO, MD, CARYN K. SNYDER, MPH, JERRY P. PALMER, MD, CHARLES T. ROBERTS, PhD DiabetOmics,
More informationType 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER
Type 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER Yes! Is Type 2 diabetes the same in kids as in adults? And No!
More informationTopic (Final-03): Immunologic Tolerance and Autoimmunity-Part II
Topic (Final-03): Immunologic Tolerance and Autoimmunity-Part II MECHANISMS OF AUTOIMMUNITY The possibility that an individual s immune system may react against autologous antigens and cause tissue injury
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationSelf-tolerance. Lack of immune responsiveness to an individual s own tissue antigens. Central Tolerance. Peripheral tolerance
Autoimmunity Self-tolerance Lack of immune responsiveness to an individual s own tissue antigens Central Tolerance Peripheral tolerance Factors Regulating Immune Response Antigen availability Properties
More informationUpdate on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016
Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM
More informationACCELERATING PROGRESS. Aaron J. Kowalski Ph.D. JDRF Chief Mission Officer
ACCELERATING PROGRESS Aaron J. Kowalski Ph.D. JDRF Chief Mission Officer March 11, 2017 OUR VISION A W RLD WITHOUT TYPE 1 DIABETES Accelerating Progress 2 OUR PURPOSE JDRF was Founded by Families Driven
More informationFlorida Network Symposium
Katrina J. Ruedy, MSPH John W. Lum, MS Jaeb Center for Health Research NE Florida Network Symposium In Conjunction with The 28th Annual Clinical Conference on Diabetes Jaeb Center for Health Research (JCHR)
More informationEffect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
Hemminki et al. Journal of Hematology & Oncology 2012, 5:59 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma
More informationAutoimmune diseases. Autoimmune diseases. Autoantibodies. Autoimmune diseases relatively common
Autoimmune diseases Fundamental abnormality: the adaptive immune system is triggered by self antigens to initiate a sustained immune response against self molecules that results in tissue injury Specificity
More informationImmune responses in autoimmune diseases
Immune responses in autoimmune diseases Erika Jensen-Jarolim Dept. of Pathophysiology Medical University Vienna CCHD Lecture January 24, 2007 Primary immune organs: Bone marrow Thymus Secondary: Lymph
More informationAtypical and Ketosis Prone Diabetes. Ashok Balasubramanyam, MD Baylor College of Medicine Houston, Texas
Atypical and Ketosis Prone Diabetes Ashok Balasubramanyam, MD Baylor College of Medicine Houston, Texas Atypical Diabetes in the Spectrum Classified as T1D Classified as T2D Auto-immune T1D T2D A- - KPD
More informationSo how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.
Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high
More informationHow Autoimmunity Develops. Thomas Kamradt Inst. f. Immunologie Klinikum der FSU Jena
How Autoimmunity Develops Thomas Kamradt Inst. f. Immunologie Klinikum der FSU Jena www.iki.uniklinik-jena.de/ immunologie@mti.uni-jena.de Autoimmunity: When the Immune System Attacks Self "Our arsenals
More informationImmunology. Lecture- 8
Immunology Lecture- 8 Immunological Disorders Immunodeficiency Autoimmune Disease Hypersensitivities Immunodeficiency 1. Immunodeficiency --> abnormal production or function of immune cells, phagocytes,
More informationForm 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Has this patient's data been previously reported to USIDNET? USIDNET ID: Today's Date: - - Date of HSCT for which
More informationPotential Rebalancing of the Immune System by Anti-CD52 Therapy
Potential Rebalancing of the Immune System by Anti-CD52 Therapy Johanne Kaplan, PhD VP Neuroimmunology Research Genzyme March 26, 2013 RESTRICTED USE SEE TRAINING MEMO 2011 DO Genzyme NOT 1COPY Corporation
More informationDiabetes in Chronic Pancreatitis: When is it type 3c? Melena Bellin, MD Associate Professor, Pediatrics & Surgery Schulze Diabetes Institute
Diabetes in Chronic Pancreatitis: When is it type 3c? Melena Bellin, MD Associate Professor, Pediatrics & Surgery Schulze Diabetes Institute Disclosure Information Melena D. Bellin Disclosure of Relevant
More informationKNOWING YOUR FAMILY HEALTH HISTORY COULD SAVE YOUR LIFE!
KNOWING YOUR FAMILY HEALTH HISTORY COULD SAVE YOUR LIFE! Why is my family health history so important? Several important reasons to know your family health history! Because some conditions run in families
More informationBachelor of Chinese Medicine ( ) AUTOIMMUNE DISEASES
Bachelor of Chinese Medicine (2002 2003) BCM II Dr. EYT Chan February 6, 2003 9:30 am 1:00 pm Rm 134 UPB AUTOIMMUNE DISEASES 1. Introduction Diseases may be the consequence of an aberrant immune response,
More informationRay A. Kroc & Robert L. Kroc. BDC Lectureship 2014
Ray A. Kroc & Robert L. Kroc BDC Lectureship 2014 Ray Kroc (Big Mack) 1902-1984 Predominant establisher of the McDonald's Corporation (1961) Philanthropist: Research and treatment of alcoholism, diabetes,
More informationAutoimmunity Origins. Horror autotoxicus: Literally, the horror of self-toxicity.
Autoimmunity Autoimmunity Origins Horror autotoxicus: Literally, the horror of self-toxicity. A term coined by the German immunologist Paul Ehrlich (1854-1915) to describe the body's innate aversion to
More informationIPS Modern management of childhood diabetes mellitus
Modern management of childhood diabetes mellitus Professor Philippe LYSY, MD PhD Pediatric endocrinology and diabetology Institut de Recherche Expérimentale et Clinique Université Catholique de Louvain
More information